We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
+19.16%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$817M
AUM Growth
+$104M
Cap. Flow
+$3.11M
Cap. Flow %
0.38%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
LCTX icon
Lineage Cell Therapeutics
LCTX
+$4.67M
2
IMDX
Insight Molecular Diagnostics
IMDX
+$1.72M

Top Sells

Rank Stock Value
1
AST
Asterias Biotherapeutics Inc. Series A
AST
+$3.28M

Sector Composition

Rank Sector Weight
1 Healthcare 55.79%
2 Consumer Staples 31.28%
3 Industrials 5.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.21B
$367M 44.97%
10,740,630
– –
MNST icon
2
Monster Beverage
MNST
$94.3B
$255M 31.28%
9,358,616
– –
IWM icon
3
iShares Russell 2000 ETF
IWM
$79.8B
$64.3M 7.87%
420,000
– –
LCTX icon
4
Lineage Cell Therapeutics
LCTX
$269M
$44.2M 5.41%
33,728,991
+3,757,430
+13% +$4.67M
AXON
5
Axon Enterprise
AXON
$42.5B
$41.4M 5.06%
760,062
– –
IMDX
6
Insight Molecular Diagnostics
IMDX
$150M
$32M 3.92%
404,913
+26,666
+7% +$1.72M
SER icon
7
Serina Therapeutics
SER
$30M
$12.1M 1.49%
85,219
– –
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
– –
-5,292,156
Closed -$3.28M

Similar funds

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.41B AUM 18.71% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return

Broadwood Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Broadwood Capital held 8 positions worth $817M, up 15% from $713M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital's Q1 2019 filing shows 2 increased and 1 closed positions. The largest sale was Asterias Biotherapeutics Inc. Series A, an estimated $3.28M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 55% a quarter earlier, followed by Consumer Staples and Industrials.

  • Broadwood Capital added most to Lineage Cell Therapeutics in Q1 2019, an estimated $4.67M increase.
  • Broadwood Capital fully exited Asterias Biotherapeutics Inc. Series A in Q1 2019, selling an estimated $3.28M.
  • Broadwood Capital's ten largest holdings make up 100% of its $817M portfolio in Q1 2019.
  • Broadwood Capital opened 0 new positions and closed 1 in Q1 2019.
  • Broadwood Capital's portfolio value rose 15% quarter-over-quarter to $817M.

Based on Broadwood Capital's 13F filing for Q1 2019, filed 15 May 2019.